2026 Interim report
Filed with HKEX · Stock code 9887 · · 97 pages · English
Nanjing Leads Biolabs Co., Ltd. on 6ix
Earlier from Nanjing Leads Biolabs
- Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
- Voluntary announcement pivotal registrational Phase IIb study of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) monotherapy in advanced EP-NEC selected as LBA and three studies selected for Proffered Paper presentations at 2026 ESMO
- WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
- Voluntary announcement updated data from phase ii clinical study of lbl-024 (opamtistomig, pd-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line treatment for nsclc presented orally at wclc 2026
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
Later from Nanjing Leads Biolabs
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Orphan Drug Designation in Japan
- Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Fast Track Designation by the U.S. FDA for first-line treatment of advanced biliary tract cancer
- Voluntary announcement first patient enrolled in phase ib/II clinical trial of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) in combination therapy for metastatic colorectal cancer
Follow Nanjing Leads Biolabs into a list and get an email when it puts out news.
Follow Nanjing Leads Biolabs